Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Tissue Response of Porfimer Sodium PDT for Peripheral Lung Tumors
NCT03344861Phase 1Completed
- Sponsor
- Concordia Laboratories
- Start
- Aug 2017
- Primary completion
- Mar 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of porfimer sodium in lung cancer and lung metastases (LM), sponsored by Concordia Laboratories. Primary endpoints: Number of Participants With at Least One Adverse Event at 108 days, Physical Examination Summaries of Non-normal Findings for Each Subject at 108 days and 3 more. Started Aug 2017; status: completed.
02
Drugs
porfimer sodium
03
Conditions
lung cancerlung metastases (LM)
Beyond the preview
Go deeper on NCT03344861.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03344861.